No Data
No Data
4D Molecular Therapeutics to Present 24-Week Interim Data for PRISM Phase 2 Trial of 4D-150 at ASRS Annual Meeting; Webcast Scheduled for July 17, 2024 at 6:30 A.m. ET to Discuss Safety and Clinical Activity Updates
24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be presented (N=30 at 3E10 vg/eye)Clinical data will be presented by Raj K. M
4DMT to Present Initial Interim 24-week Landmark Analysis From the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be presented (N=30 at 3E10 vg/eye)Clinical data will be presented by Raj K. M
BMO Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $63
BMO Capital analyst Kostas Biliouris maintains $4D Molecular Therapeutics(FDMT.US)$ with a buy rating, and maintains the target price at $63.According to TipRanks data, the analyst has a success rate
Barclays Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $45
Barclays analyst Gena Wang maintains $4D Molecular Therapeutics(FDMT.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate of 45.3% a
Reported Saturday, 4DMT Presented Injection-Free Subgroup Analyses From 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort In Wet AMD Patients With Severe Disease Activity & High Treatment Burden At The Clinical Trials Summit 2024
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher t
Express News | 4Dmt Presents Injection-Free Subgroup Analyses From 4D-150 Phase 2 Prism Randomized Dose Expansion Cohort in Wet AMD Patients With Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting